• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Fishhook in Boy's Finger

News
Poll

What's the best way to dislodge a fishhook? What if there is bony involvement?

A 3-year-old boy was at home with his cousin who was preparing for a fishing trip when a fishhook accidentally became lodged in the distal part of the child’s right middle finger. Radiographs confirmed the absence of bony infiltration.

Which statement(s) about removing a fishhook is true?

There are multiple approaches to dislodging a subcutaneous fishhook.
Advancement of the hook through an alternative site is more successful than removal through the initial point of penetration.
The best way to extract a barbed fishhook is the "cut and advance" method.
If bone involvement is suspected, imaging studies are needed to verify the hook's position before it is removed.
When bone is involved, the hook is pulled back before it is advanced through soft tissue.
Consider tetanus toxoid and prophylactic antibiotics when immunization status is unknown or not up-to-date.
All of the above are true.
Related Content
Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist

Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist

Patient Care Staff
January 15th 2025
Article

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment / image credit ©MichaelVI/stock.adobe.com

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

Grace Halsey
January 13th 2025
Article

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis / image credit ©InfiniteStudio/stock.adobe.com

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

Grace Halsey
January 10th 2025
Article

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose / image credit: ©New Africa/AdobeStock

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose

Sydney Jennings
January 8th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose

Sydney Jennings
January 6th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Accepts sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years / image credit DOCS Dermatology Rocco Serrao, MD

FDA Receives sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

Grace Halsey
December 16th 2024
Article

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

© 2025 MJH Life Sciences

All rights reserved.